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Background: Non-alcoholic steatohepatitis (NASH) is a condition that occurs during the progression of non-alcoholic
fatty liver disease. Effective therapy for NASH is still lacking. In this study, we investigated the effects of Ursodeoxycholic
acid (UDCA) in the treatment of NASH.
Methods: Western and Chinese databases were searched by independent investigators using appropriate MESH
headings to identify randomized, controlled Western and Chinese clinical trials, published between January 1990 and
October 2012, testing the effects of UDCA in patients with NASH. Patient characteristics and trial endpoints were
analyzed, with quality assessment according to widely acknowledged criteria. P < 0.05 was defined as statistically
significant in all trials.
Results: Twelve qualified randomized clinical trials, including six from China and involving 1160 subjects, were selected.
Seven of these trials assessed the effects of UDCA Monotherapy, with the other five testing combinations of UDCA
with vitamin E, polyene phosphatidylcholine, silymarin, glycyrrhizin and tiopronin. The duration of therapy ranged from
3 to 24 months, with two studies using high doses of UDCA (23–35 mg/kg/d). The average quality point was 2.69, and
was significantly lower in articles from China than in those from Western countries (2.2 ± 0.4 vs. 3.8 ± 1.1, respectively,
p < 0.05). UDCA Monotherapy significantly improved liver function in five studies and improved steatosis and fibrosis in
two studies. All five studies assessing UDCA combination therapy showed significant improvements liver function,
while two studies also improved steatosis and inflammation. One study of high-dose UDCA showed significant
improvements in ALT, γGT and liver fibrosis, whereas the other study showed no significant change in ALT and liver
pathology.
Conclusions: UDCA therapy is effective in NASH, especially when combined with other drugs. However, the low
quality of these studies and the heterogeneity of their results precluded further meta-analysis. Additional carefully
designed clinical trials are needed, especially in China.
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Non-alcoholic fatty liver disease (NAFLD), a common
pathologic condition characterized by lipid deposition in
hepatocytes, can range from simple steatosis to non-
alcoholic steatohepatitis (NASH) to fibrosis [1]. NASH
occurs in about one quarter of patients with NAFLD [2],
indicating disease progression and being a major cause
of cryptogenic cirrhosis. A retrospective study showed
that 41% of patients with NASH progressed to liver* Correspondence: jxfl007@hotmail.com
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reproduction in any medium, provided the orfibrosis and 5.4% to end-stage liver diseases [3]. The
prevalence of NASH has increased with increasing obes-
ity and type 2 diabetes, and NASH is currently estimated
to affect approximate 1% of the populations of Europe
and North America [4]. Despite the “two hit hypothesis”
for NAFLD [5], the mechanism by which it progresses to
NASH is still vague, but may include oxidative stress,
free fatty acid induced lipotoxicity, mitochondrial dys-
function, endoplasmic reticulum stress, dysregulated cy-
tokines and gut bacteria overgrowth [6].
Because of its as yet undetermined pathogenesis,
NASH therapy remains empirical and is limited to
treating associated conditions, including diabetes, obesitytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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treatment of NASH involves weight loss and increased
physical activity, which, while useful in treating simple
steatosis, is difficult for patients to achieve [7]. In Western
countries, bariatric surgery offers durable weight loss but
morbidity rates are high, preventing its further application.
Drug regimens are therefore being intensively investigated,
with those tested in the treatment of NASH including in-
sulin sensitizers such as thiazolidinediones (TZDs) and
metformin, clofibrate, betaine, glucuronate and vitamin E.
However, their effects of drugs are confusing and their ef-
ficacy unsatisfactory. For example, metformin was not su-
perior to placebo after 6 months in adults [8] and after
24 months in children [9]. Furthermore, a meta-analysis
showed that TZDs are associated with weight gain [10],
and the cardiovascular safety of glitazones has been
questioned [11]. Therefore, finding agents effective in the
treatment of NASH is of clinical importance.
Ursodeoxycholic acid (UDCA), a secondary bile acid
produced by intestinal bacteria as metabolic by product,
has been shown effective in the non-surgical treatment
of cholesterol gallstones and primary biliary cirrhosis
(PBC) [12]. The clinical properties of UDCA include
anti-apoptotic effects, lowering serum TNF-α concentra-
tions, decreasing endoplasmic reticulum stress and
improving hepatic insulin sensitivity, suggesting that
UDCA may be effective in the treatment of NASH [13].
Clinical trials of UDCA Monotherapy have yielded
contradictory results, with higher doses showing margin-
ally positive effects [14]. Trials in China of UDCA ther-
apy in patients with NASH have not been available to
Western researchers because of language limitations,
and there has been no complete overview of these data.
We therefore sought to systematically review the effects
of Western and Chinese trials of UDCA in patients with
NASH.
Methods
This systematic review was conducted according to the
format of PRIMSA [15] with certain modifications and
with the permission of local ethics committee.
Selection of studies
We searched a combinatory database of MEDLINE,
EMBASE, the Cochrane Central Register of Controlled
Trials, the Chinese Biomedicine Web Base and Chinese
scientific journals’ databases for articles published from
January 1990 to October 2012. The search strategy
used free-text words and MeSH terms to increase
sensitivity, including “UDCA”, “Ursodeoxycholic acid”,
“non-alcoholic steatohepatitis” and “NASH”. In addition,
citations in retrieved articles were screened and no lan-
guage restrictions were imposed. Available abstracts
from the Digestive Diseases Week and European UnitedGastroenterology Week conferences were also screened
and full texts were requested if necessary. To increase
the search scale, experts in the field were also consulted
for additional published and unpublished studies. The
inclusion criteria for the studies were: 1) original ran-
domized controlled trials published in either Chinese or
English, irrespective of blinding; 2) trials reporting, at
minimum, changes in liver function or histology; and 3)
treatment with a standard or high dose of UDCA, either
as Monotherapy or with other drugs.
Data extraction
Characteristics abstracted from the articles included: the
last name of the first author, the year of publication, the
location of the study, the number of subject in each
group, patient age, drug dose, duration of therapy, study
design (randomization method, blinding and number of
withdrawals), and concrete data or the effective rate of
liver function or histology normalization in patients
treated with UDCA. Data from all articles were retrieved
by Yue-fang Ye and Shao-hua Chen independently, with
the methods and results sections of these studies cut out
and coded so that the assessors were blinded to such in-
formation. Endpoint outcomes included: liver function
improvement, as assessed by alanine aminotransferase
(ALT), aspartate aminotransferase (AST) or γ-glutamyl
transpeptidase (γGT) concentration and reported as ef-
fective rate or real number change; and alleviation in
liver histology, as shown by improvements in at least
one aspect of steatosis, inflammation or fibrosis, as de-
termined by biopsy or abdominal ultrasound.
Methodology assessment and statistics
Study eligibility and methodological quality were assessed
by three investigators (Zun Xiang, Yi-peng Chen and Kui-
fen Ma) independently, with any disagreements resolved
by consensus. The methodological quality of included
studies was assessed using a five-point quality scale [16]
with minor adjustments, including the trial’s design,
double blinding, withdrawal rate, analysis and presenta-
tion. Numerical variables were compared using Student’s
t tests and categorical variables using the chi-square test.
P < 0.05 was defined as statistically significant in all analyses.
Results
Study design and characteristics
A thorough literature search, according to the previously
established medical terms, yielded a total of 224 articles
from the Western literature and 26 from the Chinese lit-
erature. Title screening precluded 176 of these articles
(78.6%). The abstracts of the remaining 48 articles were
read, and 11 articles were excluded. The full texts of the
remaining 37 articles were retrieved. Studies that lacked a
control group, verified evaluation system or randomization
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six from Western sources and six from China. These 12
studies could also be categorized into groups by UDCA
dosage, or by UDCA Monotherapy or UDCA combined
with other drugs. All 12 studies included end-point results
presented as concrete data or change in liver function and
histology.
The excluded articles included several informative
studies. In one excluded study, published in Spanish,
three patients were treated with UDCA for 1 year, with
one showing ALT and AST normalization [17]. AnotherFigure 1 Summary of the article selection process.excluded study, from the Cochrane Library, showed that
UDCA plus pentoxyphylline had significant effects on
ALT normalization and hepatic inflammation improve-
ment [18]. A third study showed that UDCA was more
effective than gemfibrozil in improving biochemical pa-
rameters in patients with NASH patients [19]. However,
the full texts of the latter two articles were unavailable.
One overlap study used the data from one trial [20] to
investigate concentrations of adipokines and apoptosis
[21]. Another, which reported that long-term treatment
with UDCA and vitamin E significantly improved ALT,
Xiang et al. BMC Gastroenterology 2013, 13:140 Page 4 of 8
http://www.biomedcentral.com/1471-230X/13/140AST, and γGT concentrations and NASH score, as well
as being well tolerated, had to be excluded because of a
lack of a placebo control [22]. Finally, a study comparing
the effects of UDCA plus vitamin E with diet and weight
management, which found significant ALT normaliza-
tion in the former group, had to be excluded because of
its retrospective design and the absence of histological
evaluation after treatment [23].
The 12 included articles [20,24-34] included a total
1160 patients, with average ages ranging from 30.5 to
50.2 years (Table 1). Six studies were from China, one
from Turkey and five from Western countries. The trials
were performed between 1996 and 2011, with seven
trials assessing UDCA Monotherapy and five evaluating
UDCA with additional agents, including vitamin E,
polyene phosphatidylcholine, silymarin, glycyrrhizin and
tiopronin. The duration of treatment ranged from 3 to
24 months. Two studies evaluated high-dose UDCA
[28,29] and six used specific drugs instead of placebo as
a control [23,25,29-31,33]. One study included three pa-
tient groups: UDCA plus vitamin E, UDCA alone and
control [20]. Compared with the control group, both
treatment groups showed significant ALT improvements,
with the UDCA plus vitamin E group also showing alle-
viation of steatosis. Therefore, the trials were separated
into separate categories, including those testing UDCA
Monotherapy, UDCA and vitamin E, and UDCA with
other drugs.
Quality assessment
Because of the stringency of this systematic review, we
evaluated the methodological quality of the 12 includedTable 1 Characteristics of the included studies
Study Year Location Number (age)a Drug
UDCA Monotherapy
Laurin et al. [24] 1996 USA 25 (46 y) vs. 16 (50 y) UDCA
Lindor et al. [25] 2004 USA/Canada 80 (45.4 y) vs. 86 (48.5 y) UDCA
Dufour et al. [20] 2006 Switzerland 18 (47 y) vs. 15 (45 y) UDCA
Kiyici et al. [26] 2003 Turkey 17 (43.7 y) vs. 27 (50.2 y) UDCA
Hong Qian, et al. [32] 2007 China 26 vs. 26 UDCA
Zhu Hong-juan [27] 2010 China 30 (42.5 y) vs. 30 (43.6 y) UDCA
Ratziu et al. [28] 2011 France 55 (49.8 y) vs. 61 (49.6 y) UDCA
Leuschner et al. [29] 2010 Germany 94 (41.5 y) vs. 91 (45.0 y) UDCA
UDCA combined with other drugs
Dufour et al. [20] 2006 Switzerland 15 (46 y) vs. 15 (45 y) UDCA
Zhuang Xue-shan [30] 2009 China 40 vs. 42 UDCA
polye
Sun Yan [31] 2007 China 76 vs. 61 UDCA
Lv Hong [33] 2005 China 40 vs. 40 UDCA
Liu Zhi-ye [34] 2006 China 96 (42.5 y) vs. 54 (47.6 y) UDCA
anumber and mean age were displayed as treatment: control group; bduration repotrials using a five-point quality scale, as described in the
Methods section (Table 2). The average score for all 12
articles was 2.69, with the score being significantly lower
for articles from China than for those from Western
countries (2.2 ± 0.4 vs. 3.8 ± 1.1, respectively, p < 0.05).
Only three articles adequately described the rando-
mization procedure: two from Western countries and
one from China (19,27,31). In most articles from Western
countries, two to seven patients withdrew from the study,
with withdrawals balanced in the treatment and control
groups. In the Chinese articles, however, either no patient
withdrew or the number was not reported, reducing the
quality of these studies. Finally, only four of the 12 studies,
all from Western countries, used double blinding. These
drawbacks precluded a meta-analysis, resulting instead in
a clinical review.
Outcome of enrolled studies
The studies tested UDCA Monotherapy or UCDA in
combination with other drugs (Table 3). UDCA Mono-
therapy was found to significantly improve liver function,
including ALT, AST or γGT, in five studies [19,23,25-27]
and to reduce steatosis and fibrosis in two studies [23,27].
All five studies of UDCA combination therapy found sig-
nificant improvements in liver function, with two also
showing improvements in steatosis and inflammation
[19,29]. These data suggested that UDCA combination
therapy was superior to UDCA Monotherapy in the treat-
ment of NASH. The results of high-dose UDCA were
contradictory, as one study [27] found significant improve-
ments in ALT, γGT and liver fibrosis while the other [28]
found no significant changes in ALT and liver pathology,(dosage) Durationb
(13-15 mg/kg/d)/Clofibrate (1 g twice daily) 12 m
(13-15 mg/kg/d)/placebo (tablet) 24 m
(13-15 mg/kg/d)/placebo (tablet) 24 m
(13-15 mg/kg/d)/Atorvastatin (10 mg/d) 6 m
(15-20 mg/kg/d)/polyene phosphatidylcholine (1368 mg/d) 6 m
(750 mg/d)/placebo (tablet) 2 m
(28-35 mg/kg/d)/placebo (tablet) 12 m
(23-28 mg/kg/d)/placebo (tablet) 18 m
(13-15 mg/kg/d) + Vitamin E (400 IU/d)/placebo (tablet) 24 m
(750 mg/d) + polyene phosphatidylcholin (1368 mg/d)/
ne phosphatidylcholine (1368 mg/d)
6 m
(300 mg/d) + Silymarin (231 mg/d)/Silymarin (231 mg/d) 3 m
(450 mg/d) + glycyrrhizin (450 mg/d)/placebo (tablet) 2 m
(900 mg/d) + Tiopronin (600 mg/d)/ UDCA (900 mg/d) 3 m
rted in months; blue indicates a higher dose of UDCA.
Table 2 Methodology quality of the included studies
Study Randomization Double blinding Withdrawn Total score
Monotherapy
Laurin et al. [24] Inadequate (no description) No 5 vs. 5 2
Lindor et al. [25] Inadequate (no description) Yes 6 vs. 2 4
Dufour et al. [20] Adequate (randomization list set up by pharmacy before study) Yes 3 vs. 2 4
Kiyici et al. [26] Inadequate (no description) No NM 2
Hong Qian, et al. [32] Adequate (1:1 ratio) NM 0 vs. 0 3
Zhu Hong-Juan [27] Inadequate (no description) No 0 vs. 0 2
Ratziu et al. [28] Adequate (1:1 ratio in blocks of four) Yes 7 vs. 3 5
Leuschner et al. [29] Inadequate (no description) Yes 39 in total 4
UDCA combined with other drugs
Dufour et al. [20] Adequate Yes 3 vs. 2 4
Zhuang Xue-shan [30] Inadequate (no description) NM 0 vs. 0 2
Sun Yan [31] Inadequate (no description) NM NM 2
Lv Hong [33] Inadequate (no description) NM NM 2
Liu Zhi-ye [34] Inadequate (no description) NM NM 2
All comparisons were treatment vs. control; NM not mentioned.
Xiang et al. BMC Gastroenterology 2013, 13:140 Page 5 of 8
http://www.biomedcentral.com/1471-230X/13/140as shown by the Brunt score and NAS score. Finally, im-
provements in liver function were easier to assess than im-
provements in liver histology, as eight of 12 studies
reported liver function improvement while only four of 12
showed improvements in liver histology.Table 3 End-point results of the included studies
Study Liver function improvement
Monotherapy
Laurin et al. [24]* ALT (−30%), ALP (−8%) and γGT (−45%)
Lindor et al. [25] ALT in −31% vs. −29%
Dufour et al. [20] ALT in −36% vs. −2%
Kiyici et al. [26] ALT in −26% vs. −40% ALT in 76.0 vs. 55.1,
γGT in 47.8vs 32.2
Hong Qian, et al. [32] Effective ratio24/26 vs. 23/27
Zhu Hong-juan [27] liver function and symptom in 25/30 vs. 15
Ratziu et al. [28] ALT in −28% vs. −2% γGT in −51% vs. +19%
Leuschner et al. [29] ALT in −41% vs. −35%
UDCA combined with other drugs
Dufour et al. [20] ALT in −42% vs. −2% AST in −30% vs. +6%
Zhuang Xue-shan [30] Effective rate 36/40 vs. 29/42
Sun Yan [31] ALT in −79 vs. −72, AST in −31 vs. −8,
Effective rate 65/76 vs. 37/61
Lv Hong [33] ALT in −45.9 vs. −16.1 AST in −40.1 vs. −29
Liu Zhi-ye [34] Effective rate 86/96 vs. 38/54
All comparisons are treatment vs. control. Red indicates statistically significant diffe
no significant changes (not shown) in liver function and histology. #, fibrosis was asSeveral studies also found that UDCA alleviated meta-
bolic markers in patients with NASH. For example, pa-
tients treated with high-dose UDCA showed significant
reductions in serum glucose, glycosylated hemoglobin
and insulin concentrations [28], as well a greater abilityHistology alleviation
steatosis improved
steatosis in −18% vs. −14%; inflammation in −0 vs. −0.1,
fibrosis in 0 vs. 0
steatosis in −13% vs. −14%, inflammation in −0.8 vs. −0.02,
fibrosis in +0.3 vs. +0.4
liver density +20% vs. +35% (in UDCA group between
after and before therapy)
not mentioned
/30 not mentioned
fibrosis in −11% vs. +10%#
Brunt score in −14% vs. −14% NAS activity score
in −21% vs. −18%
steatosis in −1.4 vs. −0.5; inflammation in −2.2 vs. −0.8
26/40 vs. 17/42 in steatosis (ultrasound)
not mentioned
.5 no report in histology
no report in histology
rences (p < 0.05). *, Data from the UDCA group; the clofibrate group showed
sessed by FibroTest, not by pathology.
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The combinations of UDCA with glycyrrhizin [33] and
tiopronin [34] showed additive triglyceride lowering ef-
fects when compared with either drug alone.
Discussion
NAFLD has become the most common chronic liver dis-
ease in Western populations, being strongly associated
with visceral obesity, insulin resistance, hypertension
and hyperlipidemia. NASH, part of the spectrum of
NAFLD, was first described in the 1970s in obese fe-
males who denied consuming alcohol [35], but generated
little interest until the end of 1980s. Because of the limi-
tations of liver biopsy, the true prevalence of NASH is
still unclear, although it is currently thought to affect
2–7% of the Western population [36]. NASH has been
found to progress to cirrhosis in 10–15% of patients,
most frequently after the fifth decade of life [3,37]. Des-
pite its clinical importance, there is still a lack of consen-
sus on NASH treatment. However, the list of potential
drugs continues to expand.
UDCA is widely used in the treatment of patients with
PBC and primary sclerosing cholangitis (PSC) and has an
excellent safety profile. The effect of UDCA in patients
with NASH remains unclear because of differences among
studies in randomization protocol, inclusion and exclusion
criteria, blinding, duration of treatment and combinations
with other drugs. Therefore, there is insufficient evidence
supporting or refuting UDCA treatment of patients with
NASH. We therefore reviewed studies in the Western and
Chinese literature, finding 12 randomized, controlled stud-
ies investigating the effects of UDCA in patients with
NASH. Although three of these articles found that
UDCA was ineffective [24,28,31], the other nine found
that UDCA had positive effects in patients with NASH,
whether as Monotherapy or combined with other drugs.
Indeed, our results suggest that UDCA is more effective
when combined with other drugs than as Monotherapy.
Although we reviewed 250 articles, we included only
12 in our analysis, a low inclusion rate. This may reflect
the relatively wide range of MESH words, our strict se-
lection criteria and the relative dearth of clinical trials in
humans. Moreover, the methodological quality of the en-
rolled studies was variable, being lower in Chinese than
in Western studies. This precluded a further meta-
analysis, but suggested that Chinese trials require a more
stringent study design.
The therapeutic effect of UDCA on NASH is biolo-
gically plausible. In an animal model, UDCA was found
to improve hepatic steatosis and inflammation [38,39],
partly by suppressing the miR-34a/SIRT1/p53 pathway
[40]. Although its mechanism of action is still unclear,
UDCA can protect hepatocytes by inhibiting the absorp-
tion of toxic hydrophobic bile salts from the smallintestine, competing with toxic bile acids to bind to cell
and organelle membranes and maintain cell membrane
stability [41]. In addition, UDCA can reduce oxidative
damage by inhibiting hydrophobic bile salt-induced
Kupffer cell activation and increasing hepatic glutathione
level s [42]. Finally, UDCA has immunomodulatory and
anti-apoptotic properties, as shown by its interaction
with the glucocorticoid nuclear receptor at the hepato-
cyte level [43], its repression of IFN-gamma induced
MHC class II gene expression [44] and its maintenance
of mitochondrial membrane stability [45].
This systematic review and the studies it included had
several limitations. First, the possibility of bias and con-
founders cannot be excluded. Although most studies in-
cluded stringent criteria for inclusion of patients with
NASH and controlled for potential confounders such as
age, sex, smoking and alcohol intake, many of these
studies could not distinguish between simple steatosis
and NASH, especially those studies lacking liver biopsy.
Second, UDCA administration and dosage varied widely
among studies, as did end point assessments, which
were evaluated as actual numbers or as changes in liver
function and histology. Third, although six of the 12 stud-
ies were performed in China, some were not published in
SCI journals, making their credibility, reliability and avail-
ability somewhat doubtful. Additional double-blinded ran-
domized clinical trials of UDCA treatment of NASH are
urgently needed. Moreover, although we evaluated their
methodological quality, some studies had low scores be-
cause of the absence of clear descriptions of the method of
randomization and the numbers of withdrawals. Fourth,
several studies showed ALT decreases in both the treat-
ment and control groups, with the differences not being
statistically significant [25,26,29]. Finally, several included
papers used liver ultrasound rather than biopsy for assess-
ment, which may impair the strength of these studies.
Conclusions
In conclusion, the findings from this systematic review
indicated that UDCA was useful in NASH therapy, espe-
cially when combined with other drugs. However, as the
selected studies differed in drug dosage and administra-
tion, assessment methods and other aspects, a meta-
analysis could not be performed. More stringent studies,
especially double-blinded randomized clinical trials, are
needed in different countries around the world.
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